All posts by medical

‘Grey’s Anatomy’: This Minor Side-Character Has Been in Every Season & Is the True Favorite of Diehard Fans – Showbiz Cheat Sheet

Throughout the 16 seasons ofGreys Anatomy, many characters have come and gone. Most recently, Alex Karev (Justin Chambers) departed the show, and fans were devastated. However, there is one character who is still a series regular that casual fans often forget about.

WithGreys Anatomycoming into its 17th season on the air, there are only a few series regulars left who have been present since day one. Meredith Grey (Ellen Pompeo) is always the star fans think of first since the show is named after her. She was married and widowed throughout her time on the long-running medical drama. In the upcoming season, we may see her find love again.

RELATED: Greys Anatomy Fans Can Finally Mark Their Calendars for the Season 17 Premiere

Miranda Bailey (Chandra Wilson) is another character who has outlasted all the rest. Her residents hated her in the early days of the show, but she quickly became another fan-favorite. In the latest season, she had a miscarriage but bonded with a teenage foster boy she later takes home.

Fans worried that James Pickens Jr. was about to depart the show in season 16 when his character, Richard Webber, nearly died. Instead, in the finale, he finally had life-saving surgery and will return for season 17.

Bokhee (Kathy C. An ) is a scrub nurse at Grey Sloan Memorial Hospital and is often featured in most surgeries. She isnt a prominent cast member and was uncredited until a recent episode because she typically has no lines. According to Greys Anatomy Fandom, An is a scrub nurse in real life and continues to work on open-heart surgeries in Los Angeles.

RELATED:Greys Anatomy Fans Predict Which Character Will Exit the Show in Season 17

Nurse BokHee appears in every season of Greys Anatomy for a total of 257 episodes, according toIMDb. She also appeared in Private Practice when she assisted during Erica Warners surgery at Seattle Grace Mercy West Hospital. The nurse also managed to make it through every round of firing during the merger with Mercy West.

Ans character is Amelia Shepherds (Caterina Scorsone) favorite scrub nurse. She also assisted Cristina Yang (Sandra Oh) while she was operating on Derek Shepherd (Patrick Dempsey) during the shooting season six.

Does she know shes basically idol-worshipped in certain corners of the internet? one fan wrote about BokHee onReddit.

Other fans chimed in that they love the scrub nurse and hope to see more of her this season.

I want a Bokhee episode! another fan added. With her history and background!

Viewers call her a treasure and love that the masses go wild for BokHee.

Many fans comment that they would love an episode dedicated to the scrub nurse and her history at the hospital.

Read the original here:
'Grey's Anatomy': This Minor Side-Character Has Been in Every Season & Is the True Favorite of Diehard Fans - Showbiz Cheat Sheet

Grey’s Anatomy: Derek Shepherd Vs. Mark Sloan – Which Character Is The Best? – Screen Rant

McDreamy and McSteamy, also known as Derek Shepherd and Mark Sloan, are two fan-favorite characters from Grey's Anatomy but which is the best?

Greys Anatomy has brought television two of the most iconic characters in hospital drama TV: McDreamy and McSteamy, or rather Derek Shepherd and Mark Sloan. Just like night and day, these two are the complete opposites of each other while also being best friends at the same time. Whats not to love?

RELATED: Grey's Anatomy: 10 Hidden Details About Derek Shepherd That Everyone Missed

With these two comes a series-long debate of which one is the better guy. Derek is dreamy and devoted whereas Mark is steamy and confident. Between the two, it was hard to pick which one Meredith should have gotten with, and its even hard now to decide which guy people would bring home to Mom for Thanksgiving. So which one is the best, Derek Shepherd or Mark Sloan?

The beauty of Mark wasnt because of his good looks or his tall stature, but also because he was just so carefree. Mark was the comic relief of the show before any of the interns came along, and he did it so well. From hilariously flirting with Meredith to taking jabs at the other residents, Mark was the life of the show when a gunman roamed the hospital or explosions happened outside.

Its a beautiful day to save lives.

With almost every episode, this quote reminded audiences that Derek was an overall great and optimistic character. His passion for what he does was told through his optimism, whether it be through that quote or the tenacity he had during his surgeries to make sure his patients stayed alive through the night. Derek believed in love, second chances, and defied the odds.

Mark was many things - sometimes a bad best friend, a player, an arrogant surgeon, but he never self-sabotaged as horribly as Derek. While Derek was going through the failure of his clinical trial, he not only punched Mark to oblivion in the middle of the hospital for everyone to see, but he also pushed Meredith away and almost ended their relationship.

RELATED:Grey's Anatomy: 5 Times Derek Shepherd Was An Overrated Character (& 5 Times He Was Underrated)

Between Mark and Derek, Mark always was the one that kept it together when life was falling down around him. Mark always knew what and who he was while Derek struggled to keep it together at times. This alone solidifies himself as one of the best.

Go here to see the original:
Grey's Anatomy: Derek Shepherd Vs. Mark Sloan - Which Character Is The Best? - Screen Rant

Camilla Luddington announces being pregnant, but will Grays Anatomy write it in? – Gruntstuff

Grays Anatomy vet Camilla Luddington introduced on Monday that she is pregnant along with her second little one which, if the ABC serial had been to write it in, positive would throw soon-to-be-ex husband Alex a curve ball!

Stemming from unique forged member Justin Chambers abrupt parting of how with Grays, the March 5 episode revealed through a sequence of handwritten letters from the MIA doc that characters learn to themselves on-screen that he had reconnected with former love Izzie and was now residing along with her in Kansas, together with their 5-year-old twins, Eli and Alexis.

Alex wrote to his spouse Jo that it felt like no time had handed when he reconnected with Izzie after years of silence. And if it had simply been a case of him lacking his first spouse, thatd be one factor. But shed had his children, through the eggs Alex had fertilized again when Izzie was combating most cancers. I want to provide these children the household you and I by no means had, he advised Jo. After I advised you I beloved you, I meant it, but Izzie has our youngsters. Ergo, the enclosed, signed divorce papers. #Ouch #StillTooSoon

As entertaining as it could be to invest that Grays will write in Luddingtons second being pregnant (after capturing round her first one, throughout Season 13), and thus give start to a bouncing bundle of dramatic irony, the very fact is that the present has stored hidden the actress being pregnant for months already, Luddington revealed. So it would seem that ship has sailed?

Luddington and her husband, Matthew Alan, have a daughter, Hayden, who turns three in April.

Read more:
Camilla Luddington announces being pregnant, but will Grays Anatomy write it in? - Gruntstuff

University of the Cumberlands students recognized for scholarship, service – The News Journal

Students Noah Thornberry (junior; Bowling Green, KY) and Mallory Allen (junior; Corbin, KY) were recently chosen as the recipients of service awards at University of the Cumberlands.

Thornberry received the 2020 T.E. Mahan Service Award, and Allen received the 2020 A.T. Siler Service Award. These awards are given to the male and female candidate from the junior class at University of the Cumberlands who best manifest the qualities which indicate the potential for becoming someone who will make an outstanding contribution to his/her community in the future. Each candidate must also have an academic standing in keeping with the standards of the University.

Noah William Thornberry, son of Mark and Ellaine Thornberry, has demonstrated exceptional service ethics and community service. His passions are service to others and real estate.

Since 2015, Thornberry has served children as a Bible school teacher at Sunday school and on summer vacations. Furthermore, he has served children in the Williamsburg area through the Mountain Outreach childrens Christmas program. While successfully balancing a demanding academic load and athletic duties, Thornberry has had the perseverance to pursue his second passion, the development of his own real estate organization. The combination of his service and leadership models both Cumberlands focus Think for tomorrow and the Universitys strategic vision to prepare students for a future life of responsible service and leadership.

Mallory Elizabeth Allen, daughter of Steve and Dawn Allen, is currently pursuing a Biology major and has maintained a 4.0 GPA. She has a heart for serving others and is deeply rooted in Cumberlands campus community.

On campus, Allen served as a volunteer resident assistant for a womens dormitory for a semester. She has served in a number of honor societies and as president of the Pre-health club. She has also volunteered for Shoes for the Soul, campus service projects, and assembling donated backpacks for food-insecure children at a local food pantry. Off campus, Allen participates in numerous volunteer activities at the Creek Church and in the Corbin Independent school system. She has volunteered for three summer mission trips to Haiti and has tutored high school students.

Professionally, Allen desires to be a physician. She has served as a teaching assistant for cell biology lab and chemistry lab, as well as being a lab technician for microbiology laboratory. In preparation for her medical school application, Allen has also attended the University of Kentucky Rural Physician Leadership Program Application Bootcamp, University of Kentucky College of Medicine Medical Education Development for Underrepresented Populations, and participated in the Rockcastle Regional Hospital Future Docs program.

University of the Cumberlands congratulates these exemplary students on being chosen for such honorable awards and thanks them for their commitment to serving their communities and being such positive influences on Cumberlands campus. Well done, Patriots!, school officials said in a release.

Originally posted here:
University of the Cumberlands students recognized for scholarship, service - The News Journal

The cell-based meat company will use the money to expand its pilot production facility. | 2020-09-28 – Meat & Poultry

MAASTRICHT, THE NETHERLANDS Mosa Meat has raised $55 million as part of a larger Series B funding round.

The Netherlands-based food technology company, which in 2013 created the worlds first cell-based hamburger patty, will use the funds to expand its current pilot production facility in Maastricht, develop an industrial-sized production line and introduce cultivated beef to consumers. No timeline has been set to bring the products to market, but the company said it is working with regulators in Europe to demonstrate the safety of cultivated beef.

The Series B funding round was led by Luxembourg-based food tech fund Blue Horizon Ventures, with participation from Bell Food Group and M Ventures.

Mosa Meat also announced Regina Hecker, partner at Blue Horizon Ventures, joined its board of directors with a special focus on science, scaling and technology. She holds a PhD in molecular and cellular biology from the University of Zurich, a masters degree in biotechnology management from the IE Business School in Madrid, a masters of engineering in biotechnology and is certified in plant-based nutrition from the T. Colin Campbell Center for Nutrition Studies.

We are excited to be joining Mosa Meat as lead investor in this round, Hecker said. Following a thorough investigation of its technology and team, we are convinced that Mosa Meat is strongly placed to pioneer the scale-up of cultured meat.

The company has reached several technical milestones recently. In 2019 it removed fetal bovine serum (FBS) from its cell culture media, the nutrient rich broth that feeds cells so they can proliferate. FBS comes from unborn calves and is the standard used in cell culturing. Mosa Meat also has lowered the cost of its animal-free media, the most expensive part of its production process, by 88%.

We are very excited to welcome our new partners and see existing partners continue our journey together, said Maarten Bosch, chief executive officer of Mosa Meat. With their support and capabilities, we have the opportunity to take the next concrete steps to scale production, make progress toward a cleaner, kinder way of making real beef and ultimately increase the resilience, sustainability and safety of our global food system.

Read the original:
The cell-based meat company will use the money to expand its pilot production facility. | 2020-09-28 - Meat & Poultry

Thwarting AAV-Neutralizing Antibodies Could Improve Gene Therapy – The Scientist

A little more than a decade ago, seven patients with hemophilia Ba disease caused by a mutation on the F9 gene that prevents patients from forming crucial clotting proteinsvolunteered to be the first humans to receive a gene therapy delivered using an adeno-associated virus as a vector. This particular treatment didnt move past the Phase 1/2 trial because, while it was deemed safe, the patients did not sustain expression of the gene. But two other gene therapies based on an adeno-associated virus (AAV), Luxturna for rare forms of blindness and Zolgensma for spinal muscular atrophy, have since been approved by the US Food and Drug Administration (FDA), and several pharmaceutical companies are now pursuing regulatory approval of AAV-carried gene therapies for hemophilia B.

Recently, scientists followed up with four of those original patients. In a study published in Molecular Therapy in September, they report that the men are still free of any worrisome toxicities related to the treatment. The study wasnt all good news, though. The team also found that after all these years, the men still had elevated levels of AAV-neutralizing antibodies. That means that if an AAV gene therapy is approved to treat their illness, they likely wont be able to benefit from itthe antibodies would chew up the vector before it could insert the corrective gene.

Administration of an AAV gene therapy is essentially a vaccine against AAV, says Lindsey George, a hematologist at the Childrens Hospital of Philadelphia who led the research. Hers was not the first study to identify antibodies as a problem for those receiving AAV gene therapies, but it is the first to show that elevated titers can last this long. This role of AAV neutralizing antibodies is huge, says George, as it stands to undermine the effectiveness of gene therapies.

Because AAVs are viruses, the human immune system creates antibodies upon exposure that recognize and neutralize them in subsequent encounters. Sometimes patients have neutralizing antibodies in their blood before ever having received a gene therapy because theyre exposed to AAVs in the environment.

The ability to effectively modulate the antibody-mediated immune response could make AAV gene therapies far more effective for far more patients than they are now.

Along with high levels of antibodies to the specific AAV vector that theyd receivedAAV2the patients Georges team evaluated also had neutralizing antibodies to several other commonly used AAV vectors, namely, AAV5 and AAV8, she tells The Scientist.

Andrew Davidoff, a pediatric surgeon at St. Jude Childrens Research Hospital who studies AAV gene therapies but was not involved in the study, says, This paper suggests that not only will they not be able to receive a second dose of vector of the same [type of AAV], but potentially even other [types].

If scientists can prevent antibodies from neutralizing the AAV, they would not only give patients like these another opportunity to receive a more effective dose of gene therapy, but it will expand the patients that we can treat with the therapy to include the 3050 percent of patients who have already been exposed to AAVs in the environment, says Giuseppe Ronzitti, who heads a lab focused on gene therapy research at Genethon.

But, Davidoff says, nobody has found a suitable solution yet that is likely to be accepted by patients. The body has evolved over millions of years, this immune system that helps fight off infections. So to overcome that, even temporarily, is not an easy task.

Some immunosuppressant drugs wont work if the body has already developed specific antibodies to a particular pathogen, such as AAV. Scientists are therefore testing combinations of different types of immunosuppressants they hope will prevent the body from attacking AAVs, but these are likely to come with major risks, chiefly, susceptibility to infection.

Another option is plasmapheresisa process in which a persons blood is removed from the body and the cells separated from the plasma so that they can be reinfused without the antibodies found in the plasmabut, like immunosuppressant drugs, the technique is nonspecific and comes with similar risks. Its a matter of risk-benefit with the continued immunosuppression, says Ronzitti.

So scientists have been looking for other ways to control the bodys response to these gene therapy vectors.

Ronzitti and his team recently proposed a solution in Nature Medicine. The scientists used the imlifidase (IdeS) protein, conditionally approved by the European Commission, to degrade immunoglobulin G (IgG) antibodies that are developed after the body encounters a specific antigen so that it can remember and target that antigen in the future, and thus might cause a patient to reject a transplanted kidney. IgG antibodies are responsible for the immune systems response to AAVs. Its a newer, less invasive alternative to plasmapheresis, Ronzitti tells The Scientist in an email.

The team injected monkeys with the IdeS protein before administering a dose of gene therapy targeting the liver. The treatment appeared safe, the monkeys levels of preexisting AAV antibodies went down, and the AAV vector successfully made its way to the liver. To model a scenario in which a patient would need more than one dose of gene therapy, the scientists administered an AAV gene therapy to another group of monkeys before giving them the IdeS protein to degrade the antibodies theyd developed in response, then readministered the gene therapy. Again, AAV antibodies diminished after the IdeS treatment and the second gene therapy dose was successfully delivered.

One drawback to the approach is that IgGs are the most prevalent type of antibody found in the blood, and destroying all of them may have undesirable side effects. In an attempt to develop a more targeted therapy, one group published a study in January demonstrating that a specialized version of plasmapheresis could reduce the levels of antibodies against human AAVs in mice to the point where a new gene therapy should be effective, without depleting all other immunoglobulins that formed in response to infections.

More recently, a team of researchers at the University of Pittsburgh Medical Center made use of CRISPR-Cas9 to increase the efficacy of AAV gene therapy in mice. Pathologist Samira Kiani and her team werent looking for ways to improve gene therapy, but instead were seeking to temporarily modulate immunity in hopes of changing the course of diseases such as septicemia, a precursor to sepsis that occurs when an infection makes its way to the blood. The researchers aimed to temporarily downregulate the Myeloid differentiation primary response 88(Myd88) gene, which would briefly dampen the immune response, and then remove the brakes.

The gene that we chose to target is known to a be a central gene for innate and adaptive immunity, says Kiani. It controls the production of IgG antibodies in response to AAV exposure, which provided a simple way to measure whether the strategy was effective. If the team administered an AAV to an animal shortly after it had received the CRISPR-Cas9 treatment, it should have a substantially lower antibody response to the virus.

First, they administered the CRISPR to tamp down Myd88 activity and measured a reduction in the expression of the Myd88 gene, as theyd expected. Then, the team used the technique to treat mice just before giving them a dose of AAV-based gene therapy that was designed to lower their cholesterol.

Weeks later, the researchers administered a second dose of the same AAV vector to determine if the temporary immunosuppression during the first dose had prevented the mice from making enough antibodies to thwart a second dose. The mice that were pretreated with the immune-modulating CRISPR showed lower levels of AAV-neutralizing antibodies and more dramatic responses to the cholesterol-lowering AAV treatment. The study was published in NatureCell Biologyin September.

If given prior to the administration of an AAV gene therapy, this approach would prevent the formation of new antibodies, so the patient could receive a second dose later, if needed, says Kiani. Given that the CRISPR treatment only prevents the development of antibodies temporarily, it shouldnt cause any long-term suppression of the rest of the immune system. On the flip side, because it doesnt clear existing antibodies, if the patients have already pre-existing antibodies [from natural exposure] this approach might not be the best approach.

All of the potential solutions have a long way to go, including still needing to be tested in human patients, but the ability to effectively modulate the antibody-mediated immune response could make AAV gene therapies far more effective for far more patients than they are now, says Ronzitti. The immune response to these vectors is quite a complex story, he says. But we are solving the issues one by one.

L. George et al., Long-term follow-up of the first in human intravascular delivery of AAV for gene transfer: AAV2-hFIX16 for severe hemophilia B,Molecular Therapy,doi:10.1016/j.ymthe.2020.06.001, 2020.

F. Moghadam et al., Synthetic immunomodulation with a CRISPR super-repressor in vivo,Nature Cell Biology,doi:10.1038/s41556-020-0563-3, 2020.

The rest is here:
Thwarting AAV-Neutralizing Antibodies Could Improve Gene Therapy - The Scientist

Predictive Analytics Detects Breast Cancer Spread with 90% Accuracy – HealthITAnalytics.com

September 28, 2020 -A predictive analytics method was able to detect with 90 percent accuracy which stage 0 breast cancers are likely to spread and recur, according to a study published in the American Journal of Physiology-Cell Physiology.

Approximately one in five new breast cancers are caught at their earliest stages, the researchers noted, but physicians arent able to confidently predict which of these stage 0 breast cancers are likely to recur and spread after surgery, or which forms surgery is likely to cure.

Understanding which aggressive a stage 0 cancer is likely to be will help doctors and their patients decide on the best course of treatment, which consists of removal of the tumor and a small amount of tissue followed by radiation, or removal of the entire breast.

To help providers better forecast the aggressiveness of these cancers, researchers developed a predictive analytics tool using samples from 70 patients who had stage 0 breast cancer. These patients had all undergone a mastectomy, and each had at least ten additional years of medical records available. Twenty of the 70 patients experienced a recurrence of their cancer, while 50 did not.

The team stained these tissue samples so that the proteins of interest would fluoresce under the microscope. Then, using a computer vision application, researchers created a library of microscope images associated with either aggressive or non-aggressive ductal carcinoma in situ (DCIS) based on what had happened to that patient.

Researchers then showed the program roughly 100 micrographs it hadnt seen before, known as holdout images, to see how well it could accurately predict whether that patients cancer was likely to recur.

The computer is looking for patterns in the images that humans cant readily discern, from the level of individual pixels up to an entire image of a million pixels, said Howard Petty, PhD, a professor of ophthalmology and visual sciences, and of microbiology and immunology at Michigan Medicine, the University of Michigans academic medical center.

The program is now able to correctly identify aggressive and non-aggressive disease 96 percent of the time, the researchers noted.

Thats pretty impressive when you consider that a human looking at these images would get the answer right about 70 percent of the time, Petty said. And weve continued to work on reducing the level of false negatives.

The tool also reported false positives in four percent of cases, meaning it identified aggressive disease in patients who did not experience recurrence.

We believe many of these examples speak to the skill of the patients surgeon, who effectively cured them of more aggressive disease in the operating room, Petty said.

Researchers plan to continue to refine the approach using additional samples, and the team expects that with further validation the tool could be approved for clinical use by the FDA within the next few years. The approach could also help providers predict the aggressiveness of similar types of cancer.

We started with a hypothesis about the biochemical mechanisms that drive cancer recurrence, tested the role of the movement of key proteins to the cell membrane in cancer recurrence and then confirmed our understanding of the underlying biology by assessing how well our explanation predicted what we actually see in patients, Petty said.

This improved understanding of the biology of cancer recurrence could also inform the development of new anti-cancer drugs.

By determining that the location of key proteins can predict a cancers aggressiveness, researchers could enhance treatment of stage 0 breast cancers.

Scientists dont really understand what leads to cancer recurrence at the molecular level and that has made it impossible to accurately predict which patients will experience a recurrence and which wont, said Petty.

What we found is that certain key enzymes collect near the cell membrane in these early breast cancers that end up being aggressive, but they dont in the cancers that are non-aggressive.

Read the rest here:
Predictive Analytics Detects Breast Cancer Spread with 90% Accuracy - HealthITAnalytics.com

This is what happens to your body over months in isolation – WXII The Triad

Since the pandemic officially began in March, we've been told staying home is the best way to avoid catching COVID-19. And it is. But life in confinement can cause physical ailments on its own.Being homebound for so long contorts the body, weakens the heart and lungs and even impairs brain function. The effects of life in isolation may stay with us beyond the pandemic's end whenever that may be.This is what half a year of isolation, staying home and staying sedentary can do to your body.You start losing muscleA week homebound, whether you're working, eating or sleeping, may feel comforting and necessary. But all the inactivity can undo hard-won progress.That's because it can take months to build muscle and just one week to lose it. Humans, for all of our hardiness, also lose muscle more quickly the older we get, said Keith Baar, a professor of molecular exercise physiology at the University of California-Davis.When you lose muscle, you're not necessarily losing bulk, but you are losing strength, which Baar said is one of the "strongest indicators" of how long you'll live."The stronger we stay, the easier it is for us to maintain our longevity."Your heart and lungs get weakerIf you're not exercising, you're not raising your heart rate. And when your heart isn't pumping as hard, it gets weaker, Baar said.The same thing happens to your lungs when you're inactive, said Dr. Panagis Galiatsatos, a pulmonologist from Johns Hopkins Bayview Medical Center. He said many of his patients have felt their breathing function deteriorate because they're no longer conditioned to exercise.People with poor lung health are already considered more susceptible to coronavirus because it's a respiratory illness, so they're likely staying home to reduce their risk of infection. But if they're not moving and increasing blood flow to their lungs, then their preexisting condition might harm them anyway.Exercise is the only key to improve both heart and lung function "Not a single medication can do that," Galiatsatos said. If it's not safe to leave the house, Baar recommends dancing or finding household objects for home strength training think milk jug deadlifts.You gain fatIf you're home all day, every day, you're likely feet away from your pantry. Depending on your perspective, that's either convenient or dangerous.With such easy access, your "feeding" window, or the period of time during which you eat most of your meals, might widen from 10 or 12 hours every day to 15 hours a day more than half the day, which could cause your insulin levels to spike. Insulin encourages fat storage and converting other fat molecules to fat, said Giles Duffield, an associate professor of anatomy and physiology at the University of Notre Dame who studies circadian rhythms and metabolism, among other subjects.Excessive eating is also an issue because, at the beginning of the pandemic, many people stocked up on nonperishable foods in case of supply shortages, Duffield said. Many nonperishable foods are highly processed and rich in sugars and starches.Weight gain during periods of intense stress is normal, and 2020 has been unrelentingly stressful. Weight gain becomes dangerous, though, when it turns into obesity. Then, your body might start to resist insulin, and chronic health issues like metabolic illness or diabetes may develop, Duffield said.Your posture is affectedWe all have a seated position we subconsciously sink into slumped forward, shoulders hunched; spine curled, neck bent; on your chest, elbows up.But sitting and lying down all day can seriously affect your posture and strain your back, neck, shoulders, hips and eyes, said Brandon Brown, an epidemiologist and associate professor in the Center for Healthy Communities at the University of California-Riverside.Brown suggests getting up from your seat once an hour, walking around and stretching for a moment. You might even lie on the floor and "let your back readjust," he said.Your sleep suffersAt least half of all Americans are skimping on vitamin D, which sustains bone density and keeps fatigue at bay. You're definitely one of them if you spend most of your day at home, curtains drawn, Duffield said.Getting enough sunlight in the morning helps synchronize your body's circadian rhythm, Duffield said. So if you're shut in all week or working in the dark, your sleep might suffer, too.Brown said as long as you're going on walks or exercising, doing yard work or other activities that drag you outside for a bit, you won't need to worry about getting enough sunlight. If you're unable to get out of the house or the weather won't permit you to, an artificial bright light can help your body retune in the morning, Duffield said, as can avoiding blue lights at night.Your brain slowsA sedentary lifestyle can slow your brain, too.Exercise produces certain chemicals in the brain that break down toxins in the blood and even prevent them from going to the brain, where they can kill brain cells, Baar said.Not exercising means you won't as efficiently break down amino acid byproducts that wind up as neurotoxins in the brain.The effects of isolation are insidious like the pandemic, the physical symptoms after months of seclusion often aren't obvious until they become harmful or extreme.It's possible, too, to stave off those symptoms before they set in for good.Prioritizing your mental and physical health while staying home requires some work, but it's a healthier coping mechanism for uncertainty than staying stationary until COVID-19 is no longer a threat, health experts say. And when it's safe to live fully again, you'll be prepared.

Since the pandemic officially began in March, we've been told staying home is the best way to avoid catching COVID-19. And it is. But life in confinement can cause physical ailments on its own.

Being homebound for so long contorts the body, weakens the heart and lungs and even impairs brain function. The effects of life in isolation may stay with us beyond the pandemic's end whenever that may be.

This is what half a year of isolation, staying home and staying sedentary can do to your body.

A week homebound, whether you're working, eating or sleeping, may feel comforting and necessary. But all the inactivity can undo hard-won progress.

That's because it can take months to build muscle and just one week to lose it. Humans, for all of our hardiness, also lose muscle more quickly the older we get, said Keith Baar, a professor of molecular exercise physiology at the University of California-Davis.

When you lose muscle, you're not necessarily losing bulk, but you are losing strength, which Baar said is one of the "strongest indicators" of how long you'll live.

"The stronger we stay, the easier it is for us to maintain our longevity."

If you're not exercising, you're not raising your heart rate. And when your heart isn't pumping as hard, it gets weaker, Baar said.

The same thing happens to your lungs when you're inactive, said Dr. Panagis Galiatsatos, a pulmonologist from Johns Hopkins Bayview Medical Center. He said many of his patients have felt their breathing function deteriorate because they're no longer conditioned to exercise.

People with poor lung health are already considered more susceptible to coronavirus because it's a respiratory illness, so they're likely staying home to reduce their risk of infection. But if they're not moving and increasing blood flow to their lungs, then their preexisting condition might harm them anyway.

Exercise is the only key to improve both heart and lung function "Not a single medication can do that," Galiatsatos said. If it's not safe to leave the house, Baar recommends dancing or finding household objects for home strength training think milk jug deadlifts.

If you're home all day, every day, you're likely feet away from your pantry. Depending on your perspective, that's either convenient or dangerous.

With such easy access, your "feeding" window, or the period of time during which you eat most of your meals, might widen from 10 or 12 hours every day to 15 hours a day more than half the day, which could cause your insulin levels to spike. Insulin encourages fat storage and converting other fat molecules to fat, said Giles Duffield, an associate professor of anatomy and physiology at the University of Notre Dame who studies circadian rhythms and metabolism, among other subjects.

Excessive eating is also an issue because, at the beginning of the pandemic, many people stocked up on nonperishable foods in case of supply shortages, Duffield said. Many nonperishable foods are highly processed and rich in sugars and starches.

Weight gain during periods of intense stress is normal, and 2020 has been unrelentingly stressful. Weight gain becomes dangerous, though, when it turns into obesity. Then, your body might start to resist insulin, and chronic health issues like metabolic illness or diabetes may develop, Duffield said.

We all have a seated position we subconsciously sink into slumped forward, shoulders hunched; spine curled, neck bent; on your chest, elbows up.

But sitting and lying down all day can seriously affect your posture and strain your back, neck, shoulders, hips and eyes, said Brandon Brown, an epidemiologist and associate professor in the Center for Healthy Communities at the University of California-Riverside.

Brown suggests getting up from your seat once an hour, walking around and stretching for a moment. You might even lie on the floor and "let your back readjust," he said.

At least half of all Americans are skimping on vitamin D, which sustains bone density and keeps fatigue at bay. You're definitely one of them if you spend most of your day at home, curtains drawn, Duffield said.

Getting enough sunlight in the morning helps synchronize your body's circadian rhythm, Duffield said. So if you're shut in all week or working in the dark, your sleep might suffer, too.

Brown said as long as you're going on walks or exercising, doing yard work or other activities that drag you outside for a bit, you won't need to worry about getting enough sunlight. If you're unable to get out of the house or the weather won't permit you to, an artificial bright light can help your body retune in the morning, Duffield said, as can avoiding blue lights at night.

A sedentary lifestyle can slow your brain, too.

Exercise produces certain chemicals in the brain that break down toxins in the blood and even prevent them from going to the brain, where they can kill brain cells, Baar said.

Not exercising means you won't as efficiently break down amino acid byproducts that wind up as neurotoxins in the brain.

The effects of isolation are insidious like the pandemic, the physical symptoms after months of seclusion often aren't obvious until they become harmful or extreme.

It's possible, too, to stave off those symptoms before they set in for good.

Prioritizing your mental and physical health while staying home requires some work, but it's a healthier coping mechanism for uncertainty than staying stationary until COVID-19 is no longer a threat, health experts say. And when it's safe to live fully again, you'll be prepared.

The rest is here:
This is what happens to your body over months in isolation - WXII The Triad

What happens to your body over months in isolation – 9News

Since the pandemic officially began in March, we've been told staying home is the best way to avoid catching COVID-19.

And it is. But life in confinement can cause physical ailments on its own.

Being homebound for so long contorts the body, weakens the heart and lungs and even impairs brain function. The effects of life in isolation may stay with us beyond the pandemic's end (whenever that may be).

This is what half a year of isolation, staying home and staying sedentary can do to your body.

A week homebound, whether you're working, eating or sleeping, may feel comforting and necessary. But all the inactivity can undo hard-won progress.

That's because it can take months to build muscle and just one week to lose it.

Humans, for all of our hardiness, also lose muscle more quickly the older we get, said Keith Baar, a professor of molecular exercise physiology at the University of California - Davis.

When you lose muscle, you're not necessarily losing bulk, but you are losing strength, which Baar said is one of the "strongest indicators" of how long you'll live.

"The stronger we stay, the easier it is for us to maintain our longevity."

Your heart and lungs get weaker

If you're not exercising, you're not raising your heart rate. And when your heart isn't pumping as hard, it gets weaker, Baar said.

The same thing happens to your lungs when you're inactive, said Dr Panagis Galiatsatos, a pulmonologist from Johns Hopkins Bayview Medical Centre.

He said many of his patients have felt their breathing function deteriorate because they're no longer conditioned to exercise.

People with poor lung health are already considered more susceptible to coronavirus because it's a respiratory illness, so they're likely staying home to reduce their risk of infection.

But if they're not moving and increasing blood flow to their lungs, then their preexisting condition might harm them anyway.

Exercise is the only key to improve both heart and lung function.

"Not a single medication can do that," Galiatsatos said.

If it's not safe to leave the house, Baar recommends dancing or finding household objects for home strength training - think milk jug deadlifts.

If you're home all day, every day, you're likely feet away from your pantry.

Depending on your perspective, that's either convenient or dangerous.

With such easy access, your "feeding" window, or the period of time during which you eat most of your meals, might widen from 10 or 12 hours every day to 15 hours a day- more than half the day, which could cause your insulin levels to spike.

Insulin encourages fat storage and converting other fat molecules to fat, said Giles Duffield, an associate professor of anatomy and physiology at the University of Notre Dame who studies circadian rhythms and metabolism, among other subjects.

Excessive eating is also an issue because, at the beginning of the pandemic, many people stocked up on nonperishable foods in case of supply shortages, Duffield said.

Many nonperishable foods are highly processed and rich in sugars and starches.

Weight gain during periods of intense stress is normal, and 2020 has been unrelentingly stressful. Weight gain becomes dangerous, though, when it turns into obesity.

Then, your body might start to resist insulin, and chronic health issues like metabolic illness or diabetes may develop, Duffield said.

We all have a seated position we subconsciously sink into - slumped forward, shoulders hunched; spine curled, neck bent; on your chest, elbows up.

But sitting and lying down all day can seriously affect your posture and strain your back, neck, shoulders, hips and eyes, said Brandon Brown, an epidemiologist and associate professor in the Center for Healthy Communities at the University of California - Riverside.

Brown suggests getting up from your seat once an hour, walking around and stretching for a moment.

You might even lie on the floor and "let your back readjust," he said.

At least half of all Americans are skimping on vitamin D, which sustains bone density and keeps fatigue at bay.

You're definitely one of them if you spend most of your day at home, curtains drawn, Duffield said.

Getting enough sunlight in the morning helps synchronize your body's circadian rhythm, Duffield said.

So if you're shut in all week or working in the dark, your sleep might suffer, too.

Brown said as long as you're going on walks or exercising, doing yard work or other activities that drag you outside for a bit, you won't need to worry about getting enough sunlight.

If you're unable to get out of the house or the weather won't permit you to, an artificial bright light can help your body retune in the morning, Duffield said, as can avoiding blue lights at night.

A sedentary lifestyle can slow your brain, too.

Exercise produces certain chemicals in the brain that break down toxins in the blood and even prevent them from going to the brain, where they can kill brain cells, Baar said.

Not exercising means you won't as efficiently break down amino acid byproducts that wind up as neurotoxins in the brain.

The effects of isolation are insidious - like the pandemic, the physical symptoms after months of seclusion often aren't obvious until they become harmful or extreme.

It's possible, too, to stave off those symptoms before they set in for good.

Prioritising your mental and physical health while staying home requires some work, but it's a healthier coping mechanism for uncertainty than staying stationary until COVID-19 is no longer a threat, health experts say.

GALLERY: One last look at Melbourne's deserted streets

And when it's safe to live fully again, you'll be prepared.

Excerpt from:
What happens to your body over months in isolation - 9News

AlzeCure Pharma provides a scientific update on Alzheimer’s disease and the Alzstatin project platform – BioSpace

STOCKHOLM, Sept. 28, 2020 /PRNewswire/ -- AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of drug candidates for diseases affecting the central nervous system, with projects in both Alzheimer's disease and pain, will hold a live business update focused on the company's Alzheimer's platform Alzstatin on Wednesday, September 30 at 10:00. The presentation will be followed by a Q&A session led by Vator Securities' analyst Felicia Rittemar.

CEO Martin Jnsson and CSO Johan Sandin will, among other things, present the pharmaceutical platform Alzstatin and the research behind it. Within the Alzstatin platform, AlzeCure develops disease-modifying and preventive drugs for Alzheimer's disease that focus on reducing the production of toxic amyloid beta (A) in the brain.

Henrik Zetterberg, chief physician and professor at the Department of Neuroscience and Physiology at Sahlgrenska Academy and professor at University College of London (UCL), will participate and provide a deeper review of disease development in Alzheimer's and the amyloid hypothesis, as well as provide an update on developments in biomarkers and diagnostics in Alzheimer's.

Watch the live broadcast on September 30 from 10:00am - 11:30am CET via: https://youtu.be/3QBa97Ue75o.

The business update will be held in English and will be available on the company's website afterwards.

The information was submitted for publication, through the agency of the contact person set out above at 10:00am CET on September 28, 2020.

About AlzeCure Pharma AB (publ)

AlzeCure is a Swedish pharmaceutical company that develops new innovative drug therapies for the treatment of severe diseases and conditions that affect the central nervous system, such as Alzheimer's disease and pain - indications for which currently available treatment is extremely limited. The company is listed on Nasdaq First North Premier Growth Market and is developing several parallel drug candidates based on three research platforms: NeuroRestore, Alzstatin and Painless.

NeuroRestore consists of three symptomatic drug candidates where the unique mechanism of action allows for multiple indications, including Alzheimer's disease, as well as cognitive disorders associated with traumatic brain injury, sleep apnea and Parkinson's disease. Alzstatin comprises two disease-modifying and preventive drug candidates for early treatment of Alzheimer's disease. Painless is the company's research platform in the field of pain and contains two projects: ACD440, which is a clinical candidate for the treatment of neuropathic pain, and TrkA-NAM, which targets severe pain in conditions such as osteoarthritis. AlzeCure aims to pursue its own projects through preclinical research and development to an early clinical phase and is continuously working with business development to find suitable out-licensing solutions with other pharmaceutical companies.

FNCA Sweden AB, +46(0)8 528 00 399 info@fnca.se, is the company's Certified Adviser. For more information, please visit http://www.alzecurepharma.se.

About Alzstatin

AlzeCure's disease-modifying research platform, Alzstatin, consisting of disease-modifying and preventive drug candidates, focuses on reducing the production of toxic amyloid beta (A) in the brain. A plays a key pathological role in Alzheimer's and begins to accumulate in the brain years before clear symptoms develop. The drug candidates in the Alzstatin platfrom modulate the function of the enzyme gamma secretase. Gamma secretase acts like a pair of scissors and cuts A42 out from a longer protein known as APP. The sticky A42 clumps together giving rise to the amyloid plaque so typical of Alzheimer's disease. The candidates in the Alzstatin platform affect enzyme function so that it instead cuts out shorter forms of the A peptide, A37 and A38, which in addition to them not being sticky and not forming aggregates, also have a restrictive effects on A42 aggregates already formed. This means the drug candidates in the Alzstatin platform have two separate but synergistic effects that together contribute to a stronger anti-amyloidogenic - and thus more potent - disease-modifyning effect.

About Alzheimer's disease

Alzheimer's disease is the most common form of dementia, affecting approximately 45 million people worldwide. Alzheimer's disease is a lethal disorder that also has a large impact on both relatives and the society. Today, preventive and disease modifying treatments are missing. The main risk factors to develop Alzheimer's are age and genetic causes. Even though the disease can start as early as between 40 and 65 years of age, it is most common after 65 years. Significant investments in Alzheimer research are being made because of the significant unmet medical need and the large cost of this disease for healthcare and society. The total global costs for dementia related diseases is estimated to about 1,000 billion USD globally in 2018. Given the lack of both effective symptomatic treatments and disease modifying treatments, the need for new effective therapies is acute.The few approved drugs on the market today have only a limited symptomatic effect and can produce dose limiting side effects. A disease modifying treatment for Alzheimer's disease is estimated to reach more than 10 billion USD in annual sales. In Sweden, approximately 100,000 people suffer from Alzheimer's disease with a healthcare cost of about 63 billion SEK yearly, which is more than for cancer and cardiovascular diseases combined.

For more information, please contactMartin JnssonCEOTel: +46-707-86-94-43martin.jonsson@alzecurepharma.com

This information was brought to you by Cision http://news.cision.com

The following files are available for download:

View original content:http://www.prnewswire.com/news-releases/alzecure-pharma-provides-a-scientific-update-on-alzheimers-disease-and-the-alzstatin-project-platform-301138830.html

SOURCE AlzeCure Pharma AB

Go here to read the rest:
AlzeCure Pharma provides a scientific update on Alzheimer's disease and the Alzstatin project platform - BioSpace